← Phreesia, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash (including restricted cash of $1,691) | $1.5m | $90.3m | $218.8m | $313.8m | $176.7m | $87.5m | $84.2m | $73.8m | |
| Accounts receivable, net of allowance for doubtful accounts of $1,523 and $1,468 as of January 31, 2026 and 2025, respectively | $16.1m | $22.0m | $29.1m | $40.3m | $51.4m | $64.9m | $73.6m | $97.5m | |
| Cardholder receivables | — | — | — | — | — | — | $0 | $38.3m | |
| Deferred purchase price receivables | — | — | — | — | — | — | $0 | $18.0m | |
| Accrued interest and fees receivables | — | — | — | — | — | — | $0 | $840k | |
| Prepaid expenses and other current assets | $3.8m | $5.2m | $7.3m | $11.0m | $10.7m | $14.5m | $15.9m | $18.0m | |
| Long-term cardholder receivables | — | — | — | — | — | — | $0 | $47.7m | |
| Long-term deferred purchase price receivables | — | — | — | — | — | — | $0 | $5.4m | |
| Total current assets | $33.3m | $131.5m | $272.3m | $386.3m | $262.4m | $195.7m | $203.3m | $279.8m | |
| Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively | — | — | $26.7m | $34.6m | $21.7m | $16.9m | $23.7m | $20.3m | |
| Capitalized internal-use software, net of accumulated amortization of $69,390 and $55,991 as of January 31, 2026 and 2025, respectively | $7.8m | $8.7m | $10.5m | $17.6m | $35.1m | $46.1m | $52.8m | $54.3m | |
| Intangible assets, net of accumulated amortization of $13,489 and $8,407 as of January 31, 2026 and 2025, respectively | $1.4m | $1.2m | $2.7m | $12.8m | $11.4m | $31.6m | $28.1m | $79.8m | |
| Goodwill | $250k | $250k | $8.3m | $33.6m | $33.7m | $75.8m | $75.8m | $170.1m | |
| Operating lease right-of-use assets | — | $0 | $2.7m | $2.3m | $569k | $266k | $1.5m | $2.0m | |
| Other assets | $710k | $180k | $1.7m | $4.2m | $3.3m | $2.9m | $2.7m | $2.4m | |
| Settlement assets | $10.2m | $12.4m | $15.5m | $19.6m | $22.6m | $28.1m | $29.2m | $33.0m | |
| Deferred contract acquisition costs | $1.5m | $1.6m | $1.2m | $2.4m | $1.8m | $986k | $583k | $338k | |
| Deferred tax assets | $0 | $775k | $658k | $515k | $81k | $0 | $0 | $1.6m | |
| Settlement obligations | $10.2m | $12.4m | $15.5m | $19.6m | $22.6m | $28.1m | $29.2m | $33.0m | |
| Current portion of operating lease liabilities | — | $0 | $1.1m | $1.3m | $934k | $393k | $964k | $1.3m | |
| Due to healthcare providers | — | — | — | — | — | — | $0 | $38.1m | |
| Deferred revenue | $6.5m | $5.4m | $10.8m | $16.5m | $17.7m | $24.1m | $32.8m | $49.5m | |
| Other current liabilities | — | — | — | — | $0 | $5.9m | $0 | $705k | |
| Operating lease liabilities, non-current | — | $0 | $1.9m | $1.3m | $349k | $134k | $646k | $1.1m | |
| Long-term due to healthcare providers | — | — | — | — | — | — | $0 | $45.3m | |
| Long-term deferred revenue | — | — | $0 | $65k | $125k | $97k | $119k | $244k | |
| Total Stockholders’ Equity | ($211.0m) | $101.9m | $263.3m | $417.3m | $287.8m | $251.4m | $264.8m | $337.2m | |
| Total Assets | $59.3m | $158.8m | $326.7m | $494.5m | $370.1m | $370.3m | $388.4m | $663.8m | |
| Total Liabilities and Stockholders’ Equity | $59.3m | $158.8m | $326.7m | $494.5m | $370.1m | $370.3m | $388.4m | $663.8m | |
| Current portion of debt and finance lease liabilities | — | $2.3m | $4.9m | $5.8m | $5.2m | $6.1m | $8.0m | $8.0m | |
| Accounts payable | $3.8m | $6.0m | $4.4m | $5.1m | $10.8m | $8.5m | $5.6m | $11.5m | |
| Accrued expenses | $5.5m | $9.2m | $18.3m | $20.1m | $21.8m | $37.1m | $37.5m | $41.3m | |
| Total current liabilities | $27.9m | $35.4m | $55.0m | $68.4m | $79.0m | $110.1m | $114.0m | $183.2m | |
| Long-term debt and finance lease liabilities | — | $21.5m | $6.5m | $7.4m | $2.7m | $5.4m | $8.2m | $92.1m | |
| Long-term deferred tax liabilities | — | — | — | — | $0 | $270k | $484k | $4.5m | |
| Other long-term liabilities | — | — | — | — | $0 | $2.9m | $185k | $47k | |
| Total Liabilities | $63.7m | $56.9m | $63.4m | $77.2m | $82.2m | $118.9m | $123.6m | $326.6m | |
| Preferred stock, undesignated, $0.01 par value—$20,000,000 shares authorized as of both January 31, 2026 and 2025; no shares issued or outstanding as of January 31, 2026 and 2025, respectively | — | — | — | — | 0 | 0 | 0 | 0 | |
| Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2026 and 2025; 62,020,186 and 60,083,444 shares issued as of January 31, 2026 and 2025, respectively | $20k | $366k | $449k | $521k | $542k | $577k | $601k | $620k | |
| Additional paid-in capital | $0 | $386.4m | $579.6m | $860.7m | $927.0m | $1.0b | $1.1b | $1.2b | |
| Accumulated deficit | ($211.0m) | ($284.5m) | ($311.8m) | ($429.9m) | ($606.1m) | ($743.0m) | ($801.5m) | ($799.2m) | |
| Accumulated other comprehensive loss | — | — | — | — | — | $0 | ($51k) | ($382k) | |
| Treasury stock, at cost, 1,355,169 shares as of both January 31, 2026 and 2025 | — | — | — | — | ($33.6m) | ($45.5m) | ($45.5m) | ($45.5m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.